Merck KGaA Profit Beats Estimates on Cost-Cutting

May 14 (Bloomberg) -- Merck KGaA, the German maker of cancer drug Erbitux, said first-quarter profit rose on higher-than-expected savings from a reorganization program, and forecast it will achieve 2014 targets a year ahead of schedule. Mark Barton reports on Bloomberg Television's "Countdown." (Source: Bloomberg)

Full Show: Bloomberg West (09/29)
21:43 - Full episode of "Bloomberg West." Guests include: Skyworks Solutions President and CEO Liam Griffin, Kargo CEO Harry Kargman and David Cowan, a partner at Bessemer Venture Partners. (Source: Bloomberg)
  • How Significant Is the Yuan's SDR Status?
  • Lockheed Martin Wins Australian Submarine Deal
  • How Much Longer Can the BOJ Overshoot Inflation?